Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Supha Pharmachem Ltd.
Source DateBoard Meeting DateDetails
25-Feb-2026 09-Mar-2026 Quarterly Results
17-Feb-2026 25-Feb-2026 Quarterly Results(Cancelled) (Cancelled)
03-Feb-2026 14-Feb-2026 Quarterly Results
06-Nov-2025 14-Nov-2025 Quarterly Results
16-Sep-2025 22-Sep-2025 Rights Issue & Increase in Authorised Capital
30-Jul-2025 04-Aug-2025 Quarterly Results
27-May-2025 30-May-2025 Audited Results
17-Apr-2025 24-Apr-2025 Inter alia, to consider and approve:- 1. To Approve the Letter of Offer (LOF) for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders of the Company. 2. Any other item with the permission of the Chair and Majority of Directors.
01-Apr-2025 07-Apr-2025 Rights Issue
10-Feb-2025 14-Feb-2025 Quarterly Results
17-Jan-2025 22-Jan-2025 Inter alia, to consider and approve:- (1) Raising funds by way of issue of fresh equity shares through Right Issue basis along-with other matter, if any, as may be permitted under applicable laws, subject to such regulatory/statutory approvals as may be required. 2) Any other business with the permission of the Chair.
11-Nov-2024 14-Nov-2024 Quarterly Results
28-Aug-2024 04-Sep-2024 (Revised) Inter alia to consider the following:- 1. To Consider Acquisition of AirOWater Global Trading LLC, UAE:The Board will review the proposal to acquire a substantial stake in AirOWater Global Trading LLC, a pioneering entity in the production of the purest form of drinking water via Atmospheric Water Generators (AWGs). This technology, recognised as one of the most sustainable solutions to the pressing issue of global water scarcity, has successfully catered to diverse sectors including Government Institutions, Corporates, Hospitality chains, Supermarkets, Hospital chains, Educational institutions, and Community Centres. 2. To Consider issuing of Foreign Currency Convertible Bonds (FCCBs). 3. Any other business with the permission of the Chair.
27-Aug-2024 03-Sep-2024 Inter alia, to transact following business:- 1. Acquisition of a company, Airowater Global Trading LLC, UAE which is into Water Injectables for Pharma Production. 2. Consideration of issuing of Foreign Currency Convertible Bonds (FCCBs) 3. Any other business with the permission of the Chair
07-Aug-2024 14-Aug-2024 Quarterly Results (Revised)
18-Jul-2024 20-Jul-2024 Increase in Authorised Capital
15-Jul-2024 08-Aug-2024 Quarterly Results
02-Jul-2024 08-Jul-2024 Inter alia to: 1. Consider and approve the proposal for fund raising through Qualified Institutional Placement (QIP): (i) To evaluate and approve the proposal to raise funds up toRs. 200,00,00,000/- (Rupees Two Hundred Crores Only) by way of issuance of equity shares, convertible securities, or other eligible instruments to Qualified Institutional Buyers (QIBs) to finance the acquisition of Good Manufacturing Practices (GMP) assets in the Active Pharmaceutical Ingredients (API) and Intermediates space, as well as the acquisition of technology, Intellectual Property (IP), including US Drug Master File (USDMF), Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP), tech packages, and other relevant assets. (ii) To determine the quantum, terms, and conditions of the QIP, including but not limited to the pricing, titning, and other relevant aspects of the issuance. (iii) To discuss and authorise the engagement of necessary intermediaries, including investment bankers, legal advisors, and other professionals for the QIP process. 2. Consider allotment of Bonus Shares to the Equity Shareholders of the Company as on record date. 3. Consider any other matter with the approval of the Board: Any other 1natters necessary to effectively implement the fund-raising and acquisition process. The Board would also consider convening an extra-ordinary general meeting/ postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal of fund raising, as required.
09-May-2024 27-May-2024 Audited Results (Revised) & Bonus issue
03-May-2024 10-May-2024 Bonus issue & Audited Results
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.